The results of a five-year early prostate cancer detection intervention

Cancer

Volumn 77, Issue 1, 1996, Pages 150-159

  Mettlin, Curtis ^a   Murphy, Gerald P ^b   Babaian, Richard J ^c   Chesley, Arthur ^d   Kane, Robert A ^e   Littrup, Peter J ^f   Mostofi, Fatoullah K ^g   Ray, Paul S ^h   Shanberg, Allen M ⁱ   Toi, Ants ^j  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ST JOSEPH S HOSPITAL   (Canada)

^e HARVARD UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^h Jr Hospital of Cook County   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

digital rectal examination; prostate cancer; prostate specific antigen; screening; ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AMERICAN CANCER SOCIETY; COHORT STUDIES; EVALUATION STUDIES; FEASIBILITY STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PALPATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 13344259322     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3     Document Type: Article

References (25)

1. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993; 43:83-91.
2. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-23.
3. Kane RA, Littrup PJ, Babaian R, Drago JR, Lee F, Chesley A, et al. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Cancer 1992; 69:1201-7.
4. Lee F, Gray JM, McLeary RD. Prostatic evaluation by transrectal sonography: criteria for diagnosis of early carcinoma. Radiology 1986; 158:91-5.
5. Dahnert WF, Hamper UM, Eggleston JC, Walsh PC, Sanders RC. Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma. Radiology 1986; 158:97-102.
6. Lee F, Torp-Pedersen ST, Littrup PJ. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989; 170:29-32.
7. Clements R, Griffiths GJ, Peeling WB. Staging prostate cancer. Clin Radiol 1992; 46:223-7.
8. Montie JE. Staging of prostate cancer. Cancer 1994; 74:1-3.
9. Gleason DF, Mellinger GT, and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64.
10. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society Guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43:42-6.
11. Feinstein AR. On the sensitivity, specificity, and discrimination of diagnostic tests. In: Feinstein AR, editor. Clinical Biostatistics. St. Louis: CV Mosby Co., 1977:214-26.
12. Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The Analysis of Case-Control Studies. LARC Scientific Publication No. 32, 1980.
13. Gann PH, Hennekens CH, Stampfer MJ. The prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-94.
14. Oesterling JE, Jacobsen SI, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4.
15. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with PSA. J Urol 1992; 147:841-5.
16. DeAntoni E, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, et al. Prostate Cancer Awareness Week, 1992: a summary of key findings. Clin Invest Med 1993; 6:448-57.
17. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, et al. Optimized strategey for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med 1993; 16:425-39.
18. Littrup PJ, Goodman AC, Mettlin CJ, Murphy GP. Cost analyses of prostate cancer screening: frameworks for discussion. J Urol 1994; 152:1873-7.
19. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, et al. Cost-effective cancer biopsies: reduction of low yield biopsies. Cancer 1994; 74:3146-58.
20. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-90.
21. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, et al. Relative sensitivity and specificity of serum PSA level compared to age-referenced PSA, PSA density and PSA change: data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74:1615-20.
22. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancers detected in the American Cancer Society National Prostate Cancer Detection Project. J Urol 1994; 152:1737-40.
23. Mostofi FK, Murphy GP, Mettlin C, Sesterhenn IA, Batsakis JG, Khaliq U, et al. Pathology review in an early prostate cancer detection project: results from the American Cancer Society National Prostate Cancer Detection Project. Prostate 1995; 27:7-15.
24. Catalona WI, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
25. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119:914-23.